• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relay Therapeutics, Inc. - Common Stock (NQ: RLAY )

    4.305 +0.145 (+3.49%)
    Streaming Delayed Price Updated: 1:16 PM EST, Dec 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Relay Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    Why Relay Therapeutics Plummeted by Nearly 14% Today
    Investors weren't happy with the company's latest effort at capital-raising. 
    Via The Motley Fool
    Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
    Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. 
    Via Benzinga
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
    Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns... 
    Via Benzinga
    AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July
    Via Benzinga
    Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
    Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... 
    Via Benzinga
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    US Stocks Higher; Dow Surges Over 200 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
    The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
    Via Talk Markets
    Topics Economy
    Exposures Economy
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
    Via Talk Markets
    RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
    RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
    Via Talk Markets
    These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
    This article identifies the 
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
    The global 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
    The global 
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.